论文部分内容阅读
目的:探讨分析垂体后叶素联合单硝酸异山梨酯治疗肺结核大咯血的临床效果。方法:选取我院2012年8月-2013年9月收治的60例应用垂体后叶素联合单硝酸异山梨酯治疗的肺结核大咯血患者作为观察组,同期收治的60例应用单纯垂体后叶素治疗的肺结核大咯血患者为对照组,观察两组患者的临床治疗效果。结果:观察组患者临床治疗总有效率为96.7%,对照组患者总有效率为85.0%,观察组患者临床效果明显优于对照组,差异具有统计学意义(p<0.05);观察组不良反应发生率为11.7%,对照组为40.0%,观察组患者不良反应发生率明显低于对照组,差异具有统计学意义(p<0.05)。结论:垂体后叶素联合单硝酸异山梨酯治疗肺结核大咯血临床效果较为显著,能有效改善患者临床症状,提高患者生活质量,值得临床应用推广。
Objective: To investigate the clinical effect of vasopressin combined with isosorbide mononitrate in treating tuberculosis hemoptysis. Methods: Sixty patients with tuberculosis and hemoptysis treated with pituitrin combined with isosorbide dinitrate in our hospital from August 2012 to September 2013 were selected as the observation group. Sixty patients treated with pituitrin Treated tuberculosis patients with hemoptysis as a control group, the clinical efficacy of two groups of patients were observed. Results: The total effective rate of clinical observation was 96.7% in observation group and 85.0% in control group. The clinical effect of observation group was better than that of control group, the difference was statistically significant (p <0.05). The adverse reactions of observation group The incidence rate was 11.7% in the control group and 40.0% in the control group. The incidence of adverse reactions in the observation group was significantly lower than that in the control group (p <0.05). Conclusion: The combination of pituitrin and isosorbide mononitrate has a significant clinical effect in treating massive tuberculosis of hemoptysis, which can effectively improve the clinical symptoms and improve the quality of life of patients, and is worthy of clinical application.